Ramelteon Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 8 mg
Reference Brands: Rozerem (USA)
Category:
Neurology
Ramelteon is available in Tablets
and strengths such as 8 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ramelteon is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ramelteon can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ramelteon is a melatonin receptor agonist used for the treatment of insomnia, specifically in adults who experience difficulty with sleep onset. It is marketed under the brand name Rozerem and acts by selectively binding to MT1 and MT2 melatonin receptors in the suprachiasmatic nucleus of the brain, the region responsible for regulating the sleep–wake cycle. By mimicking the natural action of endogenous melatonin, ramelteon helps promote the initiation of sleep without exerting sedative, anxiolytic, or muscle-relaxant effects.
Clinical studies have demonstrated that ramelteon significantly reduces latency to persistent sleep, meaning it shortens the time required to fall asleep. In controlled trials, an 8 mg dose showed a measurable reduction in sleep onset time compared to placebo, with consistent effects observed during early treatment. Meta-analyses of longer-term use indicate modest improvements in subjective sleep latency, sleep quality, and sleep efficiency, although effects on total sleep time are variable.
Ramelteon is approved for long-term use and is considered distinct from benzodiazepines and non-benzodiazepine hypnotics, as it does not cause dependence, tolerance, or rebound insomnia. Its favorable safety profile makes it a suitab
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing